Clinical trials
Immune Checkpoint Therapy clinical trials
Below are recruiting immune checkpoint therapy clinical trials, each written for real people, not researchers. We’re tracking 158 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05937295RecruitingPhase 1
Peptide vaccine plus immunotherapy for a specific cancer gene fusion
This Phase 1 study tests a custom vaccine made to match a specific cancer genetic change (DNAJB1-PRKACA fusion). It’s combined with an approved immunotherapy (immune checkpoint inhibitor) to help your immune system recognize and fight the cancer. You may be considered if your cancer is advanced or has spread and you meet several blood/organ and health requirements.
Tübingen, Baden-WürtembergAges 18 years+ - NCT07572864RecruitingPhase 2
Immunotherapy and vaccine before surgery for head and neck cancer
This trial tests a new combination of immunotherapy (a drug that helps your immune system fight cancer) and a mitochondrial vaccine given before surgery for head and neck squamous cell carcinoma. The goal is to help reduce cancer recurrence and improve survival after surgery.
Chengdu, SichuanAges 18 years+ - NCT07574047RecruitingPhase 2
Immunotherapy at different times of day for advanced melanoma
This trial tests whether giving immunotherapy at different times of the day (chrono-immunotherapy) is better for people with advanced melanoma. It looks at how timing might affect how well the treatment works and side effects.
Fribourg, Canton of FribourgAges 18 years+ - NCT07570849RecruitingPhase 2
Chidamide with chemotherapy and immunotherapy for advanced bile duct cancer
This trial tests a combination of three treatments—chidamide (a new type of cancer drug), chemotherapy, and immunotherapy—for advanced intrahepatic cholangiocarcinoma (a cancer of the bile ducts inside the liver). The goal is to see if this combination can shrink tumors and help patients live longer when used as a first treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06730503Recruiting
Glycoprotein test for lung cancer immunotherapy response
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07559929RecruitingPhase 1/Phase 2
DXC006 with immunotherapy or chemotherapy for small cell lung cancer
This trial tests a new drug called DXC006, combined with either immunotherapy (checkpoint inhibitors) or platinum-based chemotherapy, for patients with small cell lung cancer. The goal is to see if this combination works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07510724Recruiting
Real-world study of Tislelizumab for lung cancer
This trial collects information on how well the immunotherapy drug Tislelizumab works for different types of lung cancer. It is meant for people whose doctor already decided to prescribe this drug as part of their care.
Sankt Pölten, Lower AustriaAges 18 years+ - NCT06422403RecruitingPhase 2
Study on giving immunotherapy less often for advanced cancer
This trial tests whether giving certain immunotherapy drugs less often than usual is safe and still works well for people with advanced stomach, liver, or lung cancer. It might mean fewer hospital visits while still controlling the cancer.
SingaporeAges 21–99 - NCT07427186Recruiting
Studying how immunotherapy affects the immune system in early-stage cancer
This trial looks at how your immune system responds to immunotherapy given before surgery for early-stage solid tumors (like lung, head and neck, melanoma, or bladder cancer). The goal is to understand why some people respond better, so doctors can improve treatment for future patients.
ToulouseAges 18 years+ - NCT06818149Recruiting
Studying heart inflammation from immunotherapy in lung cancer
This study looks for specific markers in the blood that can help doctors better understand and treat heart inflammation (myocarditis) caused by immunotherapy in people with lung cancer. If you join, you will help find ways to improve care for other patients.
ShanghaiAges 18 years+ - NCT07421869Recruiting
Recovery from immune therapy-related hypothyroidism
This trial looks at whether patients can recover from low thyroid function caused by immune checkpoint inhibitor drugs. If you've finished immune therapy and are on thyroid medication, you may be able to stop or reduce it.
Seongnam-siAges 19 years+ - NCT07389876Recruiting
Second-line treatment for advanced stomach cancer with nab-paclitaxel
This trial tests a new chemotherapy combination for patients with advanced stomach cancer that has worsened after initial treatment. It aims to find a better second-line option using a drug called nab-paclitaxel.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07381075RecruitingPhase 2
New drug combo before surgery for head and neck cancer
This trial tests a new drug (antibody-drug conjugate) alone or with an immunotherapy drug before surgery for head and neck cancer that can be removed. The goal is to see if this combination shrinks the tumor and improves outcomes.
Chengdu, SichuanAges 18–70 - NCT05010681RecruitingPhase 2
Lenvatinib plus immunotherapy after prior liver cancer treatment
This Phase 2 trial tests lenvatinib combined with the immunotherapy drug sintilimab in people with advanced liver cancer who got worse after prior PD-1/PD-L1 treatment. It aims to slow cancer growth and improve outcomes after immune therapy hasn’t worked.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06852287RecruitingPhase 2
Study of chemo, targeted therapy, and immunotherapy for bile duct and gallbladder cancer
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
Tianjin, TiaAges 18 years+ - NCT07339488RecruitingPhase 2
Low-dose radiation and immunotherapy to shrink hard-to-remove esophageal cancer
This trial tests a treatment approach that combines low-dose radiation with immunotherapy and chemotherapy for people with esophageal cancer that is hard to remove with surgery. The goal is to shrink the tumor enough to make surgery possible, which could improve outcomes.
Shantou, GuangdongAges 18–75 - NCT07251582RecruitingPhase 3
Comparing infusion timing for lung cancer immunotherapy before surgery
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
Changsha, HunanAges 18–75 - NCT07257653RecruitingPhase 2
Cetuximab beta plus fruquintinib with or without immunotherapy for first-line advanced colorectal cancer
This trial tests a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without an immunotherapy drug for people with a specific type of advanced colorectal cancer that has not been treated before. It aims to see if this approach is safe and effective for those whose tumors have certain genetic markers (RAS and BRAF wild type).
Hangzhou, ZhejiangAges 10–85 - NCT06107608Recruiting
Scan for tumors in lung cancer patients on immunotherapy
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
BrusselsAges 18 years+ - NCT07186621RecruitingPhase 3
Testing immunotherapy or chemoembolization after liver cancer surgery
This trial compares two treatments after liver cancer surgery to see which better prevents the cancer from coming back. You may be eligible if your surgery had a narrow margin and you have certain risk factors, like a tumor over 5 cm or high AFP levels.
BeijingAges 18–80 - NCT07161310Recruiting
Urolithin A with immunotherapy for newly diagnosed solid tumors
This trial tests adding a natural supplement called urolithin A to standard first-line immunotherapy for people with newly diagnosed solid tumors who have not yet had any cancer treatment. The goal is to see if it makes the immunotherapy work better.
FrankfurtAges 18 years+ - NCT07138222Recruiting
Immune therapy and fertility in women and men with melanoma
This study looks at how immune checkpoint inhibitors (a type of immunotherapy) affect fertility and hormone health in premenopausal women and men with melanoma. It aims to understand and manage these side effects while you receive treatment.
Sydney, New South WalesAges 18–60 - NCT07141056Recruiting
Emotional stress and immunotherapy for liver cancer
This study looks at how emotional stress affects how well immunotherapy works for liver cancer. It is for people with liver cancer who are about to start immunotherapy, either before or after surgery, or as first treatment for advanced cancer.
Zhanjiang, GuangdongAges 18 years+ - NCT07130032RecruitingPhase 2
Immunotherapy combo for advanced lung cancer or melanoma
This trial tests a combination of immunotherapy drugs (anti-PD-1/PD-L1 antibodies) plus bevacizumab and a low-dose chemotherapy called cyclophosphamide for people with advanced lung cancer or melanoma who have already been on immunotherapy and their cancer has progressed.
Saint Petersburg, Sankt-PeterburgAges 18 years+
Hear when a new Immune Checkpoint Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immune checkpoint therapy?
- Yes. Clin2 currently lists 158 recruiting immune checkpoint therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune checkpoint therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune checkpoint therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.